Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089495 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL8070439 | 0.88 | HTR1A (0.62) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL28825400 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL28866778 | 0.83 | CYP2C9 (0.59) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL19049515 | 0.83 | LMNA (0.61) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL874574 | 0.83 | CYP1A2 (0.59) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL30089425 | 0.83 | CYP1A2 (0.59) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL17260408 | 0.81 | GRK2 (0.53) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL5748829 | 0.81 | POLB (0.64) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL29025384 | 0.80 | POLB (0.60) | SMN1; SMN2CYP2C9CYP2C19CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0166875-A1 | 3-[2-(2-Benzimidazolyl)-benzoyloxyethyl]-4(3H)-quinazolinone, process for its preparation and medicine containing this product | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1986-01-08 | — | — | EP | claimed |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3723759-B1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023205272-A1 | PYRAZINAMIDE COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205272-A1 | PYRAZINAMIDE COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-108276352-B | Nitrogen-containing heterocyclic compound with nematicidal activity and preparation method and application thereof | 华东理工大学 | 2022-09-20 | — | — | CN | disclosed |
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2021-11-04 | — | — | US | disclosed |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2021-07-22 | — | — | US | disclosed |
| EP-3723759-A2 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A. (BR) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019113668-A2 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2019-06-20 | — | — | WO | disclosed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | disclosed |
| US-8735578-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2014-05-27 | — | — | US | disclosed |
| EP-2619187-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | Aché Laboratórios Farmacêuticos S.A. (BR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037634-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2012-03-29 | — | — | WO | disclosed |
| WO-1993021163-A1 | QUINAZOLONES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1993-10-28 | — | — | WO | disclosed |
| US-4599415-A | 3-(2-(2-benzimidazolyl) benzolyloxyethyl)-4(3H)-quinazolinone | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1986-07-08 | — | — | US | disclosed |
| US-4599415-A | 3-(2-(2-benzimidazolyl) benzolyloxyethyl)-4(3H)-quinazolinone | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1986-07-08 | — | — | US | disclosed |
| EP-0166875-A1 | 3-[2-(2-Benzimidazolyl)-benzoyloxyethyl]-4(3H)-quinazolinone, process for its preparation and medicine containing this product | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1986-01-08 | — | — | EP | disclosed |
| EP-0166875-A1 | 3-[2-(2-Benzimidazolyl)-benzoyloxyethyl]-4(3H)-quinazolinone, process for its preparation and medicine containing this product | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | SMN1; SMN2 4142/4885CYP2C9 734/4885CYP2C19 122/4885 |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR1A | SMN1; SMN2 4194/4885CYP2C9 528/4885CYP2C19 83/4885 |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR5A, HTR2A, HTR2C | SMN1; SMN2 4139/4885CYP2C9 529/4885CYP2C19 84/4885 |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | HTR5A, HTR3C, FKBP5 | SMN1; SMN2 3877/4885CYP2C9 404/4885CYP2C19 121/4885 |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | PC, GOT2, PCK2 | SMN1; SMN2 4142/4885CYP2C9 939/4885CYP2C19 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.